Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.37
HBIO's Cash to Debt is ranked lower than
75% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.42 vs. HBIO: 0.37 )
Ranked among companies with meaningful Cash to Debt only.
HBIO' s 10-Year Cash to Debt Range
Min: 0.37  Med: 1.44 Max: N/A
Current: 0.37
Equity to Asset 0.68
HBIO's Equity to Asset is ranked higher than
67% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. HBIO: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
HBIO' s 10-Year Equity to Asset Range
Min: 0.68  Med: 0.76 Max: 0.93
Current: 0.68
0.68
0.93
Interest Coverage 6.68
HBIO's Interest Coverage is ranked lower than
81% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. HBIO: 6.68 )
Ranked among companies with meaningful Interest Coverage only.
HBIO' s 10-Year Interest Coverage Range
Min: 1.61  Med: 15.09 Max: 9999.99
Current: 6.68
1.61
9999.99
F-Score: 8
Z-Score: 2.87
M-Score: -2.39
WACC vs ROIC
14.18%
1.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 3.81
HBIO's Operating margin (%) is ranked lower than
54% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. HBIO: 3.81 )
Ranked among companies with meaningful Operating margin (%) only.
HBIO' s 10-Year Operating margin (%) Range
Min: -33.77  Med: 8.80 Max: 19.85
Current: 3.81
-33.77
19.85
Net-margin (%) 0.22
HBIO's Net-margin (%) is ranked lower than
63% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.95 vs. HBIO: 0.22 )
Ranked among companies with meaningful Net-margin (%) only.
HBIO' s 10-Year Net-margin (%) Range
Min: -163.11  Med: 1.28 Max: 17.58
Current: 0.22
-163.11
17.58
ROE (%) 0.25
HBIO's ROE (%) is ranked lower than
62% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.63 vs. HBIO: 0.25 )
Ranked among companies with meaningful ROE (%) only.
HBIO' s 10-Year ROE (%) Range
Min: -679.29  Med: 1.62 Max: 22.98
Current: 0.25
-679.29
22.98
ROA (%) 0.17
HBIO's ROA (%) is ranked lower than
61% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.88 vs. HBIO: 0.17 )
Ranked among companies with meaningful ROA (%) only.
HBIO' s 10-Year ROA (%) Range
Min: -211.43  Med: 1.26 Max: 16.39
Current: 0.17
-211.43
16.39
ROC (Joel Greenblatt) (%) 7.95
HBIO's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. HBIO: 7.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -962.9  Med: 21.29 Max: 43.82
Current: 7.95
-962.9
43.82
Revenue Growth (3Y)(%) -3.60
HBIO's Revenue Growth (3Y)(%) is ranked lower than
77% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. HBIO: -3.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HBIO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23.7  Med: 3.50 Max: 11.4
Current: -3.6
-23.7
11.4
EBITDA Growth (3Y)(%) -3.30
HBIO's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. HBIO: -3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HBIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.8  Med: -3.10 Max: 29.1
Current: -3.3
-28.8
29.1
EPS Growth (3Y)(%) -18.60
HBIO's EPS Growth (3Y)(%) is ranked lower than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. HBIO: -18.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HBIO' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.7  Med: 4.60 Max: 171.4
Current: -18.6
-68.7
171.4
» HBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

HBIO Guru Trades in Q2 2014

Jim Simons 740,400 sh (+26.66%)
Zeke Ashton 300,000 sh (+5.26%)
Chuck Royce 767,100 sh (unchged)
John Hussman 930,000 sh (unchged)
Arnold Van Den Berg 190,130 sh (unchged)
» More
Q3 2014

HBIO Guru Trades in Q3 2014

Chuck Royce 774,800 sh (+1.00%)
John Hussman 930,000 sh (unchged)
Arnold Van Den Berg 190,130 sh (unchged)
Zeke Ashton 271,600 sh (-9.47%)
Jim Simons 632,100 sh (-14.63%)
» More
Q4 2014

HBIO Guru Trades in Q4 2014

Arnold Van Den Berg 191,225 sh (+0.58%)
Chuck Royce 774,800 sh (unchged)
John Hussman 908,000 sh (-2.37%)
Jim Simons 599,719 sh (-5.12%)
Zeke Ashton 50,000 sh (-81.59%)
» More
Q1 2015

HBIO Guru Trades in Q1 2015

Jim Simons 609,200 sh (+1.58%)
Chuck Royce 784,800 sh (+1.29%)
Zeke Ashton Sold Out
John Hussman Sold Out
Arnold Van Den Berg Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 628.90
HBIO's P/E(ttm) is ranked lower than
98% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.10 vs. HBIO: 628.90 )
Ranked among companies with meaningful P/E(ttm) only.
HBIO' s 10-Year P/E(ttm) Range
Min: 3.71  Med: 31.14 Max: 732.22
Current: 628.9
3.71
732.22
Forward P/E 50.51
HBIO's Forward P/E is ranked lower than
88% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.98 vs. HBIO: 50.51 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 648.90
HBIO's PE(NRI) is ranked lower than
99% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.00 vs. HBIO: 648.90 )
Ranked among companies with meaningful PE(NRI) only.
HBIO' s 10-Year PE(NRI) Range
Min: 3.69  Med: 17.51 Max: 732.22
Current: 648.9
3.69
732.22
P/B 2.07
HBIO's P/B is ranked higher than
62% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. HBIO: 2.07 )
Ranked among companies with meaningful P/B only.
HBIO' s 10-Year P/B Range
Min: 0.63  Med: 1.17 Max: 2.43
Current: 2.07
0.63
2.43
P/S 1.73
HBIO's P/S is ranked higher than
68% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. HBIO: 1.73 )
Ranked among companies with meaningful P/S only.
HBIO' s 10-Year P/S Range
Min: 0.51  Med: 1.17 Max: 2.02
Current: 1.73
0.51
2.02
POCF 70.75
HBIO's POCF is ranked lower than
87% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.89 vs. HBIO: 70.75 )
Ranked among companies with meaningful POCF only.
HBIO' s 10-Year POCF Range
Min: 4.6  Med: 12.29 Max: 82.38
Current: 70.75
4.6
82.38
EV-to-EBIT 81.06
HBIO's EV-to-EBIT is ranked lower than
91% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.04 vs. HBIO: 81.06 )
Ranked among companies with meaningful EV-to-EBIT only.
HBIO' s 10-Year EV-to-EBIT Range
Min: 4.7  Med: 12.90 Max: 106
Current: 81.06
4.7
106
Shiller P/E 27.22
HBIO's Shiller P/E is ranked higher than
56% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.41 vs. HBIO: 27.22 )
Ranked among companies with meaningful Shiller P/E only.
HBIO' s 10-Year Shiller P/E Range
Min: 9.46  Med: 18.57 Max: 41.33
Current: 27.22
9.46
41.33
Current Ratio 2.67
HBIO's Current Ratio is ranked higher than
56% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.56 vs. HBIO: 2.67 )
Ranked among companies with meaningful Current Ratio only.
HBIO' s 10-Year Current Ratio Range
Min: 1.97  Med: 3.96 Max: 11.53
Current: 2.67
1.97
11.53
Quick Ratio 1.55
HBIO's Quick Ratio is ranked lower than
55% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. HBIO: 1.55 )
Ranked among companies with meaningful Quick Ratio only.
HBIO' s 10-Year Quick Ratio Range
Min: 1.15  Med: 2.97 Max: 10.71
Current: 1.55
1.15
10.71
Days Inventory 114.98
HBIO's Days Inventory is ranked higher than
57% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 125.77 vs. HBIO: 114.98 )
Ranked among companies with meaningful Days Inventory only.
HBIO' s 10-Year Days Inventory Range
Min: 40.88  Med: 107.85 Max: 274.71
Current: 114.98
40.88
274.71
Days Sales Outstanding 53.89
HBIO's Days Sales Outstanding is ranked higher than
65% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. HBIO: 53.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
HBIO' s 10-Year Days Sales Outstanding Range
Min: 47.14  Med: 61.24 Max: 104.4
Current: 53.89
47.14
104.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.96
HBIO's Price/Net Current Asset Value is ranked lower than
80% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.96 vs. HBIO: 20.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HBIO' s 10-Year Price/Net Current Asset Value Range
Min: 1.89  Med: 3.73 Max: 21.56
Current: 20.96
1.89
21.56
Price/Tangible Book 7.26
HBIO's Price/Tangible Book is ranked lower than
71% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.32 vs. HBIO: 7.26 )
Ranked among companies with meaningful Price/Tangible Book only.
HBIO' s 10-Year Price/Tangible Book Range
Min: 1.65  Med: 2.95 Max: 7.46
Current: 7.26
1.65
7.46
Price/Projected FCF 1.42
HBIO's Price/Projected FCF is ranked higher than
64% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. HBIO: 1.42 )
Ranked among companies with meaningful Price/Projected FCF only.
HBIO' s 10-Year Price/Projected FCF Range
Min: 0.48  Med: 0.83 Max: 1.46
Current: 1.42
0.48
1.46
Price/Median PS Value 1.49
HBIO's Price/Median PS Value is ranked lower than
68% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. HBIO: 1.49 )
Ranked among companies with meaningful Price/Median PS Value only.
HBIO' s 10-Year Price/Median PS Value Range
Min: 0.61  Med: 1.06 Max: 4.09
Current: 1.49
0.61
4.09
Price/Graham Number 16.17
HBIO's Price/Graham Number is ranked lower than
99% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. HBIO: 16.17 )
Ranked among companies with meaningful Price/Graham Number only.
HBIO' s 10-Year Price/Graham Number Range
Min: 0.67  Med: 1.58 Max: 113.75
Current: 16.17
0.67
113.75
Earnings Yield (Greenblatt) (%) 1.23
HBIO's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. HBIO: 1.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HBIO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.9  Med: 7.80 Max: 21.2
Current: 1.23
0.9
21.2
Forward Rate of Return (Yacktman) (%) -16.31
HBIO's Forward Rate of Return (Yacktman) (%) is ranked lower than
88% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.68 vs. HBIO: -16.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HBIO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -16.6  Med: 6.00 Max: 18.4
Current: -16.31
-16.6
18.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HBI.Germany,
Harvard Bioscience Inc is a Delaware corporation, which began its business in 1901. The Company developer, manufacturer and marketer of scientific instruments, systems and lab consumables used to advance life science for basic research, drug discovery, clinical and environmental testing. It has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada, and China. The Company sells its products to researchers in over 100 countries through its sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. The Company core product range is organized into five product families: Fluidics, Lab Equipment and Supplies, Molecular Analysis, Cell Physiology, and Animal Physiology. It primarily sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI, and CMA Microdialysis. The Fluidics product family includes Company's traditional syringe pump and peristaltic pump product lines. The products are used in many life science and industrial applications that require accurately controlled fluid dispensing, including infusion, perfusion, cellular microinjection, microfluidics, mass spectrometry calibration, electrospinning and microdialysis. The primary brands are Harvard Apparatus, Harvard Pumps, and KD Scientific. The Lab Equipment and Supplies product family includes products for molecular biology labs with a liquid handling focus. It consists of pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables. Its brands include Denville Scientific, AHN, and others. The Molecular Analysis product family includes spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments. The Company sells spectrophotometers under the names Libra, WPA and BioDrop. The Cell Physiology product family consists of electrophysiology products. The Animal Physiology product family includes instruments and accessories for tissue, organ and animal based lab research, including surgical products, infusion systems, microdialysis instruments, behavior research systems, isolated organ and tissue bath systems, bioreactors for regenerative medicine research, and in vivo electrophysiology recording and stimulation systems. Its product offerings are marketed through Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS and TBSI brands and entities. The Company competes with several companies that provides instruments for life science research including, Lonza Group Ltd., Becton D
» More Articles for HBIO

Headlines

Articles On GuruFocus.com
Latest Stock Trades from Century Management: Buys POT, HWCC, PICO, AU, KGC Jan 15 2014 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 05 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Harvard Bioscience Inc, BGC Partners Inc., Chatham Lodg Sep 25 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Spartech Corp, Harvard Bioscience Inc, Rural/Metro Corp Sep 18 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 09 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Aug 10 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q/A) Feb 19 2009 
Harvard Bioscience, Inc. Schedules Fourth Quarter 2008 Conference Call for February 26, 2009 Feb 09 2009 

More From Other Websites
Harvard Bioscience to Join the Russell 3000 and Russell Global Indexes Jun 23 2015
Harvard Bioscience to Join the Russell 3000 and Russell Global Indexes Jun 23 2015
Why Harvard Bioscience (HBIO) Could Be Positioned for a Slump - Tale of the Tape May 27 2015
10-Q for Harvard Bioscience, Inc. May 09 2015
10-K for Harvard Bioscience, Inc. May 06 2015
Harvard Bioscience Inc Earnings Call scheduled for 11:00 am ET today Apr 30 2015
Harvard Bioscience reports 1Q loss Apr 30 2015
Harvard Bioscience reports 1Q loss Apr 30 2015
Harvard Bioscience Appoints James Green to the Board of Directors and Announces Retirement of Robert... Apr 30 2015
Harvard Bioscience Reports First Quarter 2015 Financial Results Apr 30 2015
Q1 2015 Harvard Bioscience Inc Earnings Release - Before Market Open Apr 30 2015
Harvard Bioscience Appoints James Green to the Board of Directors and Announces Retirement of Robert... Apr 30 2015
Harvard Bioscience Reports First Quarter 2015 Financial Results Apr 30 2015
Skanska booked a $51M write-down following Harvard split Apr 30 2015
Harvard Bioscience Schedules First Quarter 2015 Conference Call for April 30 at 11:00 AM ET Apr 21 2015
Harvard Bioscience Schedules First Quarter 2015 Conference Call for April 30 at 11:00 AM ET Apr 21 2015
Harvard Bioscience posts 4Q loss Feb 26 2015
Harvard Bioscience posts 4Q loss Feb 26 2015
Harvard Bioscience Fourth Quarter 2014 Non-GAAP EPS Increases 100% Versus Fourth Quarter 2013 on... Feb 26 2015
Harvard Bioscience Appoints Ryan Atienza to Vice President of Sales at Its Denville Scientific... Feb 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK